To the Editor In an extended follow-up of the Escitalopram for Depression in Acute Coronary Syndrome (EsDEPACS) trial, Dr Kim and colleagues randomized 300 patients with recent acute coronary syndrome (ACS) and major or minor depression to receive 24 weeks of escitalopram (n = 149) or placebo (n = 151) and reported significantly fewer major adverse cardiac events (MACE) a median of 8.1 years later in the escitalopram group.1 As noted by the authors, previous trials have not observed similar reductions in cardiac events or mortality. Kim and colleagues offered several possible explanations for these divergent findings, but several additional issues merit consideration.
Thombs BD, Ziegelstein RC. Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome. JAMA. 2018;320(20):2151. doi:10.1001/jama.2018.15922
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: